Schering-sponsored Seldane study shows declines in co-administration of contraindicated drugs.
SELDANE OVERLAPPING USE WITH CONTRAINDICATED DRUGS DECLINED FROM 5.4% TO 2.3% between January 1990 and June 1994, Brookline, Mass.-based Policy Analysis researchers David Thompson, PhD, and Gerry Oster, PhD, report in a study published in the May 1 issue of the Journal of American Medical Association. The retrospective study was funded by Hoechst Marion Roussel competitor Schering-Plough, which markets the antihistamine Claritin.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth